We extend our sincere appreciation for the support of our corporate sponsors. Their generosity provides vital funding needed to fulfill our mission to make a lasting and positive difference in the lives of people who have kidney disease.
THANK YOU TO OUR CORPORATE PARTNERS
Fresenius Kidney Care, a division of Fresenius Medical Care North America (FMCNA), provides dialysis treatment and services to more than 190,000 people with kidney disease at more than 2,400 facilities nationwide. Fresenius Kidney Care supports people by helping to address both the physical and emotional aspects of kidney disease through personalized care, education and lifestyle support services so they can lead meaningful and fulfilling lives.
U.S. Renal Care serves more than 23,000 patients in 300 dialysis facilities in 31 states and the Territory of Guam with a unique business model, developing and operating dialysis centers in joint venture partnerships with leading local nephrologists.
Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.
Akebia Therapeutics is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health. Our mission is to change the management of disease worldwide by using information gained from a simple blood draw to proactively inform treatment.
Dialysis Clinic, Inc. (DCI) is the nation’s largest non-profit dialysis provider with over 230 outpatient dialysis clinics in 28 states. DCI’s services include in-center hemodialysis, home hemodialysis, and Peritoneal Dialysis.
Sanifit is a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders. The company is a spin-off from the University of the Balearic Islands, and has offices in Spain and the U.S. Sanifit’s lead compound, SNF472, is a novel small molecule, and a selective and potent inhibitor of hydroxyapatite (HAP) crystallization, the final common pathway that leads to vascular calcification. Its clinical development is focused on two indications in End Stage Kidney Disease (ESKD) patients; calciphylaxis and peripheral artery disease (PAD).
Ardelyx is dedicated to improving the lives of patients by developing and commercializing first-in-class targeted therapies that advance patient care. Using our discovery model, Ardelyx scientists have identified new biological mechanisms and pathways that have enabled us to develop a pipeline of drug candidates designed to better manage complications related to kidney and cardiorenal diseases with the goal of improving outcomes for this large population of underserved patients.
Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people’s lives. Discover how our rich history of innovation and patient-centered solutions has helped influence our vision for the future.
OneLegacy saves and heals lives through organ, eye and tissue donation, comforts the families we serve, and inspires our communities to Donate Life. OneLegacy envisions a day when we fulfill the needs of donor families and all who require organ, cornea or tissue transplants for their health and well-being. We commit ourselves to continuously improve the quality of our practices, performance, and service to our communities.